USPTO serial 88664224
VYDAPTIV
Reviewed by CopyMark Law Group
Status 606
- Filing date
- Status date
- Registration date
- —
- Examiner
- PARK, JENNY K
- Law office
- INTENT TO USE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with VYDAPTIV?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Monica Riva Talley
Monica Riva Talley STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.1100 NEW YORK AVENUE, N.W.WASHINGTON, DC 20005UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Therapeutic protein molecules used in the manufacture of pharmaceutics and biologically-derived medical preparations; all the foregoing to exclude such molecules relating to antibiotics and pharmaceutical preparations for the treatment and prophylaxis of infectious diseases | ACTIVE | — |
| 005 | Pharmaceutical preparations containing polypeptides, antibodies, or antibody derivatives for the treatment and prophylaxis of cancer and immune system diseases and disorders, and autoimmune system diseases, namely, neurological and neuromuscular diseases and disorders, gastrointestinal diseases, nervous system diseases and disorders, respiratory system diseases, lymphatic system diseases, primary and secondary immunodeficiency disorders, genetic autoimmune diseases, severe combined immunodeficiency diseases, immune complex diseases, and immunodeficiency diseases, including, allergies, asthma, diabetes, rheumatoid arthritis, multiple sclerosis, lupus, Hashimoto's, inflammatory bowel disease, Guillain-Barre, psoriasis, chronic inflammatory demyelinating polyneuropathy (CIPD), Graves' disease, myasthenia gravis, and transplant rejection diseases, and blood disorders, all of the foregoing to exclude antibiotics and pharmaceutical preparations for the treatment and prophylaxis of infectious diseases | ACTIVE | — |
| 042 | Research and development in the pharmaceutical and biotechnology fields relating to polypeptides, antibodies or antibody derivatives, in relation to the treatment and prophylaxis of cancer, immune system diseases and disorders, and autoimmune system diseases, namely, neurological and neuromuscular diseases and disorders, gastrointestinal diseases, nervous system diseases and disorders, respiratory system diseases, lymphatic system diseases, primary and secondary immunodeficiency disorders, genetic autoimmune diseases, severe combined immunodeficiency diseases, immune complex diseases, and immunodeficiency diseases, including, allergies, asthma, diabetes, rheumatoid arthritis, multiple sclerosis, lupus, Hashimoto's, inflammatory bowel disease, Guillain-Barre, psoriasis, chronic inflammatory demyelinating polyneuropathy (CIPD), Graves' disease, myasthenia gravis, and transplant rejection diseases, and blood disorders, all of the foregoing to exclude research and development in relation to antibiotics and the treatment and prophylaxis of infectious diseases | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Aptevo Therapeutics, Inc.
- Other trademarks owned by Aptevo Therapeutics, Inc.
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 042
- Similar marks named VYDAPTIV
- Prosecution event MAB6 explained
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| May 30, 2023 | MAB6 | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| May 29, 2023 | ABN6 | ABANDONMENT - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Nov 8, 2022 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Nov 7, 2022 | EX5G | SOU EXTENSION 5 GRANTED | — |
| Nov 7, 2022 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Oct 28, 2022 | EXT5 | SOU EXTENSION 5 FILED | — |
| Oct 28, 2022 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Apr 30, 2022 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Apr 28, 2022 | EX4G | SOU EXTENSION 4 GRANTED | — |
| Apr 28, 2022 | EXT4 | SOU EXTENSION 4 FILED | — |
| Apr 28, 2022 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Oct 30, 2021 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Oct 28, 2021 | EX3G | SOU EXTENSION 3 GRANTED | — |
| Oct 28, 2021 | EXT3 | SOU EXTENSION 3 FILED | — |
| Oct 28, 2021 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Apr 30, 2021 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Apr 28, 2021 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Apr 28, 2021 | EXT2 | SOU EXTENSION 2 FILED | — |
| Apr 28, 2021 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Oct 28, 2020 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Oct 26, 2020 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Oct 26, 2020 | EXT1 | SOU EXTENSION 1 FILED | — |
| Oct 26, 2020 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Apr 28, 2020 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Mar 3, 2020 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Mar 3, 2020 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Feb 12, 2020 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jan 28, 2020 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jan 28, 2020 | DOCK | ASSIGNED TO EXAMINER | — |
| Oct 28, 2019 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Oct 25, 2019 | NWAP | NEW APPLICATION ENTERED | — |